Total Funding
67
56
Total FundingGrant raised
Growth Score
0 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
142452
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells.
Per Straten: Co-founder and Scientific AdvisorPast Role: SurVac, Co-Founder
Henrik Stage: CFOPast Role: SynAct Pharma, CFO
About the Company
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells.
Overexpression of RhoC protein is a characteristic of most type of metastatic cancer cells. The cancer vaccine product RV001, already in clinical trial, recognises cells with high concentration of RhoC and stimulate the immune
system to target them. RhoVac’s concept focuses on eliminating cancer cells having metastatic potential that escape treatment of the parent tumour via other methods.
The company is based in Sweden and Denmark and is publicly traded in Swedish stock market. RhoVac is managed and advised by a senior team of executives with extensive expertise built upon years of experience.
